Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 1
1999 1
2000 1
2001 2
2003 1
2005 3
2008 1
2009 3
2010 2
2012 3
2013 1
2014 1
2015 3
2016 4
2017 1
2018 5
2020 1
2021 3
2022 4
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.
Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, Narita M, O'Brien R, Peloquin CA, Raftery A, Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A. Nahid P, et al. Clin Infect Dis. 2016 Oct 1;63(7):e147-e195. doi: 10.1093/cid/ciw376. Epub 2016 Aug 10. Clin Infect Dis. 2016. PMID: 27516382 Free PMC article.
Given the public health implications of prompt diagnosis and effective management of tuberculosis, empiric multidrug treatment is initiated in almost all situations in which active tuberculosis is suspected. Additional characteristics such as presence …
Given the public health implications of prompt diagnosis and effective management of tuberculosis, empiric multidrug treatm …
Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines.
Schito M, Migliori GB, Fletcher HA, McNerney R, Centis R, D'Ambrosio L, Bates M, Kibiki G, Kapata N, Corrah T, Bomanji J, Vilaplana C, Johnson D, Mwaba P, Maeurer M, Zumla A. Schito M, et al. Clin Infect Dis. 2015 Oct 15;61Suppl 3(Suppl 3):S102-18. doi: 10.1093/cid/civ609. Clin Infect Dis. 2015. PMID: 26409271 Free PMC article.
Since the failure of the MVA85A vaccine 2 years ago, there have been no new tuberculosis vaccine candidates entering clinical testing. The current status quo of the lengthy treatment duration and poor treatment outcomes associated with MDR/XDR …
Since the failure of the MVA85A vaccine 2 years ago, there have been no new tuberculosis vaccine candidates entering clinical testing …
Antimicrobial for 7 or 14 Days for Febrile Urinary Tract Infection in Men: A Multicenter Noninferiority Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
Lafaurie M, Chevret S, Fontaine JP, Mongiat-Artus P, de Lastours V, Escaut L, Jaureguiberry S, Bernard L, Bruyere F, Gatey C, Abgrall S, Ferreyra M, Aumaitre H, Aparicio C, Garrait V, Meyssonnier V, Bourgarit-Durand A, Chabrol A, Piet E, Talarmin JP, Morrier M, Canoui E, Charlier C, Etienne M, Pacanowski J, Grall N, Desseaux K, Empana-Barat F, Madeleine I, Bercot B, Molina JM, Lefort A; PROSTASHORT Study Group. Lafaurie M, et al. Clin Infect Dis. 2023 Jun 16;76(12):2154-2162. doi: 10.1093/cid/ciad070. Clin Infect Dis. 2023. PMID: 36785526 Clinical Trial.
BACKGROUND: The optimal duration of antimicrobial therapy for urinary tract infections (UTIs) in men remains controversial. ...In the intention-to-treat analysis, treatment success occurred in 64 participants (55.7%) in the 7-day group and in 97 partic …
BACKGROUND: The optimal duration of antimicrobial therapy for urinary tract infections (UTIs) in men remains controversial. .. …
Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease.
Haley CA, Schechter MC, Ashkin D, Peloquin CA, Peter Cegielski J, Andrino BB, Burgos M, Caloia LA, Chen L, Colon-Semidey A, DeSilva MB, Dhanireddy S, Dorman SE, Dworkin FF, Hammond-Epstein H, Easton AV, Gaensbauer JT, Ghassemieh B, Gomez ME, Horne D, Jasuja S, Jones BA, Kaplan LJ, Khan AE, Kracen E, Labuda S, Landers KM, Lardizabal AA, Lasley MT, Letzer DM, Lopes VK, Lubelchek RJ, Patricia Macias C, Mihalyov A, Misch EA, Murray JA, Narita M, Nilsen DM, Ninneman MJ, Ogawa L, Oladele A, Overman M, Ray SM, Ritger KA, Rowlinson MC, Sabuwala N, Schiller TM, Schwartz LE, Spitters C, Thomson DB, Tresgallo RR, Valois P, Goswami ND; BPaL Implementation Group. Haley CA, et al. Clin Infect Dis. 2023 Oct 5;77(7):1053-1062. doi: 10.1093/cid/ciad312. Clin Infect Dis. 2023. PMID: 37249079 Free PMC article.
The median BPaL duration was 6 months. CONCLUSIONS: BPaL has transformed treatment for rifampin-resistant or intolerant tuberculosis. In this cohort, effective treatment required less than half the duration recommended in 2019 US guidelin …
The median BPaL duration was 6 months. CONCLUSIONS: BPaL has transformed treatment for rifampin-resistant or intolerant tub …
Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort.
Hewison C, Khan U, Bastard M, Lachenal N, Coutisson S, Osso E, Ahmed S, Khan P, Franke MF, Rich ML, Varaine F, Melikyan N, Seung KJ, Adenov M, Adnan S, Danielyan N, Islam S, Janmohamed A, Karakozian H, Kamene Kimenye M, Kirakosyan O, Kholikulov B, Krisnanda A, Kumsa A, Leblanc G, Lecca L, Nkuebe M, Mamsa S, Padayachee S, Thit P, Mitnick CD, Huerga H. Hewison C, et al. Clin Infect Dis. 2022 Sep 29;75(6):1006-1013. doi: 10.1093/cid/ciac019. Clin Infect Dis. 2022. PMID: 35028659 Free PMC article.
BACKGROUND: Safety of treatment for multidrug-resistant tuberculosis (MDR/RR-TB) can be an obstacle to treatment completion. ...CONCLUSIONS: AEs often related to linezolid and injectable drugs were more common than those frequently attributed to bedaquiline a …
BACKGROUND: Safety of treatment for multidrug-resistant tuberculosis (MDR/RR-TB) can be an obstacle to treatment comple …
Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis.
Khan FA, Minion J, Pai M, Royce S, Burman W, Harries AD, Menzies D. Khan FA, et al. Clin Infect Dis. 2010 May 1;50(9):1288-99. doi: 10.1086/651686. Clin Infect Dis. 2010. PMID: 20353364 Review.
METHODS: A systematic review and meta-analysis of randomized, controlled trials and cohort studies was conducted to evaluate the impact of duration and dosing schedule of rifamycin and use of antiretroviral therapy in the treatment of active tubercu …
METHODS: A systematic review and meta-analysis of randomized, controlled trials and cohort studies was conducted to evaluate the impa …
Treatment Outcomes of Multidrug-Resistant Tuberculosis in Taiwan: Tackling Loss to Follow-up.
Yu MC, Chiang CY, Lee JJ, Chien ST, Lin CJ, Lee SW, Lin CB, Yang WT, Wu YH, Huang YW. Yu MC, et al. Clin Infect Dis. 2018 Jul 2;67(2):202-210. doi: 10.1093/cid/ciy066. Clin Infect Dis. 2018. PMID: 29394358 Free PMC article.
BACKGROUND: The proportion of treatment success among patients with multidrug-resistant tuberculosis (MDR-TB) enrolled between 1992 and 1996 was 51.2%, and that among patients enrolled between 2000 and April 2007 was 61%. ...METHODS: Comprehensive care was provided …
BACKGROUND: The proportion of treatment success among patients with multidrug-resistant tuberculosis (MDR-TB) enrolled between …
Adverse Events Associated With Treatment for Pan-Susceptible Tuberculosis in San Francisco.
Louie JK, Keh C, Agraz-Lara R, Phillips A, Graves S. Louie JK, et al. Clin Infect Dis. 2023 Mar 21;76(6):1121-1124. doi: 10.1093/cid/ciac867. Clin Infect Dis. 2023. PMID: 36322073
Of 373 patients treated for drug-susceptible tuberculosis, 35.4% (46.2% aged 65 years) developed moderate/severe adverse events that required treatment interruption (34.8%), first-line drug discontinuation (26.2%, primarily pyrazinamide), second-line drug initiation …
Of 373 patients treated for drug-susceptible tuberculosis, 35.4% (46.2% aged 65 years) developed moderate/severe adverse events that …
Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials.
Feller M, Huwiler K, Schoepfer A, Shang A, Furrer H, Egger M. Feller M, et al. Clin Infect Dis. 2010 Feb 15;50(4):473-80. doi: 10.1086/649923. Clin Infect Dis. 2010. PMID: 20067425 Free article. Review.
BACKGROUND: We investigated the effectiveness of long-term antibiotic treatment in patients with Crohn's disease. ...Results from intention-to-treat analyses were combined in a random-effects meta-analysis, stratified by class of drug. Odds ratios (ORs …
BACKGROUND: We investigated the effectiveness of long-term antibiotic treatment in patients with Crohn's disease. ...Results f …
The Impact of Preventive Treatment for Multidrug- and Rifampin-Resistant Tuberculosis Exceeds Trial-Based Estimates.
Kasaie P, Pennington J, Gupta A, Dowdy DW, Kendall EA. Kasaie P, et al. Clin Infect Dis. 2024 Jan 25;78(1):133-143. doi: 10.1093/cid/ciad557. Clin Infect Dis. 2024. PMID: 37724763
BACKGROUND: Several clinical trials of tuberculosis preventive treatment (TPT) for household contacts of patients with multidrug- or rifampin-resistant tuberculosis (MDR/RR-TB) are nearing completion. ...This NNT decreased to 54 with 13-18 years of observatio …
BACKGROUND: Several clinical trials of tuberculosis preventive treatment (TPT) for household contacts of patients with multidr …
48 results